CMS Reviews Medicare Coverage With Evidence Development May 9
This article was originally published in The Pink Sheet Daily
Open door forum will consider factors in providing Coverage with Evidence Development. Part B drugs are eligible for CED; comment deadline on CED draft guidance is June 6.
You may also be interested in...
Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.
Amgen, J&J, Sanofi-Aventis, Pfizer, Merck, Roche, Lilly and Schering-Plough are scheduled to report results in upcoming week. Bristol could expand upon plans to sell OTC unit to Novartis the following week.
Homeland Security/Emergency Preparedness Subcommittee and Government Reform Committee hearings will focus on countermeasure procurement issues and evaluating the effectiveness of the BioShield Act of 2004.